Search results
Results from the WOW.Com Content Network
When most tumors metastasize to the lung, they form distinct nodules, but about 7% spread through the lymph vessels of the lung. [2] They may impair breathing in several ways; the lung becomes stiffer; blood vessels traveling alongside the distended lymph vessels become compressed. [3]
From there it spreads in fairly predictable pattern. Typically, if lung cancer spreads, it first goes to nearby lymph nodes, followed by lymph nodes further away located between the lungs in a space called the mediastinum. In the mediastinum, the lung cancer tends at first to stay on the side where the original tumor started. Once it crosses ...
Lung cancer, also known as lung carcinoma, is a malignant tumor that begins in the lung. Lung cancer is caused by genetic damage to the DNA of cells in the airways, often caused by cigarette smoking or inhaling damaging chemicals. Damaged airway cells gain the ability to multiply unchecked, causing the growth of a tumor.
For example, a benign tumor of smooth muscle cells is called a leiomyoma (the common name of this frequently occurring benign tumor in the uterus is fibroid). Confusingly, some types of cancer use the -noma suffix, examples including melanoma and seminoma .
A sarcoma is a malignant tumor, a type of cancer that arises from cells of mesenchymal (connective tissue) origin. [1] [2] Connective tissue is a broad term that includes bone, cartilage, muscle, fat, vascular, or other structural tissues, and sarcomas can arise in any of these types of tissues.
In 2016, the FDA approved atezolizumab for the treatment of people with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy and pembrolizumab for the treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors express programmed death-ligand 1 as ...
Lung cancers are now considered a large and extremely heterogeneous family of neoplasms [4] that feature widely varying genetic, biological, and clinical characteristics. . About 50 different lung cancer variants are recognized under the 2004 revision of the World Health Organization ("WHO-2004") histological typing system, the most widely recognized and used lung cancer classification sche
However, as SCL are considered particularly aggressive non-small cell lung cancers, [2] some experts recommend particularly aggressive treatment approach to these tumors. Little is known about the effects of EGFR inhibitors in SC, although some evidence suggests that these tumors are not likely to be highly responsive.